Month: June 2026

Release – Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

Posted on by [email protected]

Research News and Market Data on CVKD

Company to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to global pharmaceutical partners at the 2026 BIO International Convention in San Diego

Kawasaki disease is the leading cause of acquired heart disease in children in developed nations. Patients are at risk of forming blood clots in coronary arteries and may require lifelong treatment

If the designation is granted and tecarfarin is approved for this indication, Cadrenal would be eligible to receive a Priority Review Voucher-recent open-market valuations for these vouchers have reached into the ~$200 million range

PONTE VEDRA, Fla., June 18, 2026 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company advancing late-stage novel therapies for life-threatening immune and thrombotic conditions, today announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the U.S. Food and Drug Administration (FDA) for tecarfarin as a treatment for pediatric patients with Kawasaki disease (KD) who develop coronary artery aneurysms (CAAs) and require chronic oral anticoagulation.

The announcement comes ahead of the BIO International Convention, June 22-25, 2026, in San Diego, California. Cardenal’s executive leadership team will highlight this rare pediatric initiative and its Phase 3-ready CAD-1005 platform during one-on-one partnering meetings with global and regional pharmaceutical companies.

KD is an acute inflammatory illness and the leading cause of acquired heart disease in children in developed nations. Up to 25% of untreated children with KD develop enlarged coronary arteries or CAAs. Patients with large CAAs are at risk for forming blood clots in those blood vessels – with a continuing lifelong risk for subsequent heart attacks and sudden cardiac death – and require chronic, precise anticoagulation therapy to reduce their higher risk of clot formation.

Tecarfarin is a novel, next-generation Vitamin K antagonist (VKA) that offers a number of potential advantages over warfarin, the current standard VKA in clinical use. Specifically, tecarfarin is designed to overcome limitations of warfarin metabolism and potentially provide more reliable and more consistent anticoagulation than might be possible with warfarin.

“Children with large or giant aneurysms due to KD represent an important underserved orphan population,” said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics. “The current standard of care – warfarin – is notoriously unstable in children because of dietary variations, concurrent medications, and genetic differences in liver metabolism. Tecarfarin is metabolized in a completely different way than warfarin, and is being developed to offer a highly stable, predictable alternative. We believe tecarfarin can potentially improve time in therapeutic range for these children, thereby lowering their risk for both catastrophic blood clots and dangerous bleeding events.”

The FDA’s RPDD program targets serious or life-threatening diseases that primarily affect fewer than 200,000 people in the United States from birth through age 18. If the FDA grants the designation and tecarfarin is subsequently approved for this indication, Cadrenal would be eligible to receive a Priority Review Voucher (PRV). These transferable vouchers can be used to accelerate the FDA review of a future drug or sold to another pharmaceutical manufacturer. Following Congress’s extension of the pediatric PRV program through September 30, 2029, recent open-market valuations for these vouchers have reached record highs, with recent sales ranging from $180 million to $205 million.

At the upcoming BIO International Convention, Cadrenal will present a dual-track portfolio strategy designed to maximize value for potential partners:

  • The Global Pharma Track: Focusing on CAD-1005, a first-in-class 12-LOX inhibitor. CAD-1005 is Phase 3-ready for Heparin-Induced Thrombocytopenia (HIT) and is advancing into a Phase 2a trial for Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), addressing a combined, multi-billion-dollar dual-indication acute hospital care market.
  • The Regional & Rare Disease Track: Focusing on tecarfarin for Kawasaki disease. This program offers an efficient clinical trial design and strong geographic synergy, particularly for Japanese and East Asian pharmaceutical companies, where the incidence of Kawasaki disease is historically 10 to 15 times higher than in Western nations.

“Our presence at BIO 2026 centers on executing capital-efficient development strategies,” added Mr. Pham. “If we are successful in advancing tecarfarin toward a RPDD, we will create a high-value, de-risked regulatory pathway that aligns with regional partners’ portfolio needs while directing our core internal resources toward our blockbuster CAD-1005 critical care franchise.”

About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics is a biopharmaceutical company advancing late-stage novel therapies for life-threatening immune and thrombotic conditions. The company’s pipeline includes CAD-1005, a novel first-in-class 12-LOX inhibitor targeting multiple critical care indications, and tecarfarin, a late-stage oral anticoagulant designed to avoid CYP450 metabolism. CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration, as well as orphan drug status from the European Medicines Agency, for the treatment of Heparin-Induced Thrombocytopenia (HIT). CAD-1005 is also being developed for use in Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), and second-generation 12-LOX oral therapeutics are in development for chronic indications.

About Tecarfarin

The Company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease and those with left ventricular assist devices. Tecarfarin has also received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration.

Safe Harbor Statement

Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include, without limitation, statements regarding plans to file for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease; Cadrenal being eligible to receive a Priority Review Voucher and the value of the voucher; tecarfarin offering a number of potential advantages over warfarin, tecarfarin overcoming limitations of warfarin metabolism and potentially providing more reliable and more consistent anticoagulation than might be possible with warfarin; tecarfarin offering a highly stable, predictable alternative to warfarin; tecarfarin potentially improving time in therapeutic range for these children, thereby lowering their risk for both catastrophic blood clots and dangerous bleeding events and the successful advancement of tecarfarin creating a high-value, de-risked regulatory pathway that aligns with regional partners’ portfolio needs while directing the Company’s core internal resources toward its CAD-1005 critical care franchise Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to raise sufficient capital to continue progress of CAD-1005; the ability for tecarfarin to receive a Rare Pediatric Disease Designation for treatment of Kawasaki Disease; the ability to monetize a priority review voucher if received, the ability to successfully design and complete a dual-track portfolio strategy and maximize value for potential partners; the ability of tecarfarin to overcome limitations of warfarin metabolism and potentially provide more reliable and more consistent anticoagulation than might be possible with warfarin; the ability of tecarfarin offering a highly stable, predictable alternative to warfarin; tecarfarin potentially improving time in therapeutic range for children with Kawasaki Disease, thereby lowering their risk for both catastrophic blood clots and dangerous bleeding events and the successful advancement of tecarfarin creating a high-value, de-risked regulatory pathway that aligns with regional partners’ portfolio needs; ; the ability to successfully design and complete the Phase 3 study and derive the results needed for an NDA submission: and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.

For more information, please contact:

Lytham Partners, LLC, Robert Blum, Managing Partner, 602-889-9700, [email protected]

Primary Logo

Release – MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University

Posted on by [email protected]
Primary Logo

Research News and Market Data on MAIA

June 18, 2026 8:30am EDT Download as PDF

Georgia’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide

CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the third U.S. clinical site in its Phase 2 THIO-101 expansion trial, Winship Cancer Institute of Emory University (“Winship”), is activated and now enrolling patients. The trial studies MAIA’s lead investigational telomere-targeting agent, ateganosine, as a third-line (3L) treatment for non-small cell lung cancer (NSCLC).

Matthew Failor, Director of Clinical Operations for MAIA, commented, “Winship is Georgia’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center and is recognized at the forefront of cancer innovation and discovery nationwide. Winship offers a renowned thoracic oncology clinical research program with a proven track record in clinical trial development and conduct. With its premier medical team and extensive body of research, this cancer center is well-suited for our U.S. Phase 2 trial of ateganosine.”

The principal investigator for the THIO-101 expansion trial at Winship is Ticiana Leal, M.D., a professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine. Dr. Leal’s clinical research focuses on trials involving chemotherapy and immunotherapy agents for lung cancer.

Dr. Leal commented, “At Winship, we serve the state of Georgia and surrounding states where innovation in lung cancer treatment is a broad, underserved need. In Georgia, lung cancer is the leading cause of cancer-related deaths, with over 7,300 new cases in 2025. MAIA’s novel ateganosine agent, if approved, could address a significant gap in clinical care for the advanced-stage NSCLC patient population where there are no FDA-approved options available for treatment.”

THIO-101 is an ongoing Phase 2, open-label trial evaluating ateganosine followed by cemiplimab for NSCLC patients resistant to checkpoint inhibitors and chemotherapy. Parts A and B of the trial have shown strong early efficacy, with some patients showing survival exceeding two years, and now MAIA continues to expand the trial in the U.S.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101 Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
[email protected]

Primary Logo

Source: MAIA Biotechnology, Inc.

Released June 18, 2026

Pump Prices Fall Under $4 Just in Time for Summer Travel Season

Posted on by [email protected]

The energy shock that defined the spring of 2026 is unwinding, and American consumers are feeling it at the pump just in time for summer. The national average price of regular gasoline fell to $3.99 per gallon Thursday, dropping below the $4 threshold for the first time in months and delivering meaningful relief to households that watched prices climb above $4.50 per gallon only a month ago at the height of the US-Iran conflict.

For the small and microcap companies that spent the spring absorbing elevated fuel costs with limited ability to pass them through, the decline is more than a consumer story. It is the early stage of a margin recovery that could reshape the second half of the year.

What’s Driving the Decline

The catalyst is diplomatic. Following President Trump’s announcement Sunday that Washington and Tehran had agreed to terms on a 60-day memorandum of understanding aimed at ending the three-month conflict and reopening the Strait of Hormuz to commercial traffic, crude oil prices have fallen sharply. Brent crude, the international benchmark, has dropped roughly 13% over the past five trading sessions to trade firmly below $80 per barrel for the first time since the early days of the war. US benchmark WTI crude has fallen even harder, shedding approximately 15% to trade below $75.

The scale of the recovery reflects the scale of the disruption. The shuttering of the Strait of Hormuz removed more than one billion barrels of oil from the global market over three months, creating one of the most severe supply squeezes in years. Gasoline and other crude derivatives, which carry embedded refining costs and are stored in smaller quantities, experienced even more dramatic price swings than crude itself — which is precisely why they are now falling quickly as the supply picture normalizes.

Industry analysts project the national average could head toward $3.70 per gallon in the near term as the Iran agreement takes hold and movement through the strait resumes, with diesel prices expected to fall below $5 per gallon shortly after.

The Small Cap Margin Story

For consumer-facing companies in the sub-$2 billion market cap range, the decline in fuel costs is a direct and measurable tailwind. Throughout the spring, regional trucking companies, last-mile delivery operators, food service businesses, and logistics providers absorbed surging diesel and gasoline costs that compressed already thin operating margins. Unlike large cap peers with hedging programs and pricing power, smaller operators had few options beyond eating the costs or risking demand destruction by raising prices.

That pressure is now reversing. Lower fuel costs flow almost immediately through to the operating expenses of transportation and logistics-dependent companies. Credit card data throughout the spring showed consumers spending an increasing share of their budgets on gasoline while cutting back elsewhere — a dynamic that squeezed discretionary small cap retailers and restaurant operators. As pump prices fall, that discretionary spending capacity returns, potentially benefiting the consumer-facing companies that had been most pressured.

The Caveats Worth Watching

The recovery is not without risk. Gasoline prices remain elevated above prewar levels, and a well-documented market phenomenon often described as “rockets and feathers” means pump prices tend to rise quickly when crude climbs but fall more slowly on the way back down. The timing of the Strait of Hormuz fully reopening remains uncertain, which means oil prices are unlikely to collapse dramatically as summer driving demand builds.

A more immediate threat comes from the weather. Tropical Storm Arthur is expected to impact the US Gulf Coast, home to the nation’s largest refinery complex. With US refineries already running at 97% of capacity according to federal data, any disruption from flooding could squeeze a system operating at its limit and temporarily reverse some of the relief now reaching consumers.

Barring significant storm damage or other disruptions, analysts project national average gasoline prices could fall below $3 per gallon by year-end, with diesel below $4. For the small cap companies that endured the spring squeeze, that would represent a full-circle recovery — and a meaningful tailwind heading into 2027.

Lands’ End (LE) – Multiple Paths to Value Creation

Posted on by [email protected]


Thursday, June 18, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating coverage. The transformational WHP Global partnership unlocks hidden brand value by monetizing the Lands’ End intellectual property portfolio, eliminating significant balance-sheet risk, and providing access to WHP’s global licensing platform. In our view, the market is underappreciating the long-term earnings potential from licensing expansion and future profit-sharing opportunities.

A significantly strengthened balance sheet. Lands’ End fully repaid its $234 million term loan, reduced annual interest expense by more than $30 million, and provided substantial financial flexibility. The company now has the capacity to reinvest in growth initiatives while executing its recently authorized $100 million share repurchase program.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

First Phosphate Corp. (FRSPF) – First Phosphate Gains Strategic G7 Support for Critical Minerals Supply Chain Development

Posted on by [email protected]


Thursday, June 18, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2026 G7 Summit in France. First Phosphate Corp. announced that it has secured international investment support and formalized offtake agreements under the Critical Minerals Resilience and Production Alliance at the 2026 G7 Summit in Evian, France. The developments underscore the company’s strategic importance in the effort by G7 nations and allied partners to develop secure and diversified critical mineral supply chains, particularly for lithium iron phosphate (LFP) battery production.

International Investment Support. First Phosphate has secured a letter of interest (LOI) from the Export and Investment Fund of Denmark (EIFO) for up to C$275 million in guarantees to support development of the Begin-Lamarche mine. The company has also received letters of interest from the Italian Export Credit Agency (SACE), from Italy’s National Promotional Institution, Cassa Depositi e Prestiti (CDP), and from the international growth partner for Italian companies (SIMEST). First Phosphate has also received support from the Italian engineering group MAIRE, with respect to First Phosphate’s phosphoric acid plant at Port Saguenay, to deploy Ballestra S.p.A (Italy) technology.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Intel Surges on Reported Apple Deal as One of the Year’s Most Dramatic Turnarounds Gains Steam

Posted on by [email protected]

Intel (Nasdaq: INTC) stock soared more than 11% Thursday after President Trump posted on Truth Social that Apple has agreed to work with the chipmaker to build its processors. The announcement followed an earlier Wall Street Journal report that the two companies had reached a preliminary agreement under which Intel would manufacture chips for the iPhone maker. Intel declined to comment on the report.

The move caps an extraordinary run for a company that was written off by much of Wall Street barely a year ago. Intel stock has now climbed more than 250% since the start of 2026 and roughly 500% over the past twelve months, making it one of the most dramatic corporate turnarounds in the technology sector.

Why the Apple Report Matters

The significance of a potential Apple partnership is as much symbolic as it is financial. Apple previously relied on Intel chips for its laptops and desktops before abandoning the company in favor of designing its own custom silicon — a high-profile departure that came to symbolize Intel’s competitive decline over the past decade. A renewed manufacturing relationship, even a modest one, would represent a meaningful reversal of that narrative.

Industry analysts have tempered expectations on the initial scope. Early commentary suggests any first agreement would likely involve lower-volume, less critical components rather than Apple’s flagship processors. Intel will need to prove its manufacturing reliability before earning more substantial business. But as analysts noted, the first step is always the hardest — and Intel appears to be taking it.

A Foundry Strategy Finally Paying Off

The Apple report does not exist in isolation. It is the latest in a series of developments validating Intel’s multi-year effort to build out its foundry business — the arm of the company that manufactures chips for third-party customers rather than just for Intel itself. Recent reports indicate Intel will build three million Tensor Processing Units for Google, and that Nvidia is exploring using Intel to fabricate some of its own processors. Earlier this week, Intel announced that its latest 18A-P processor node has entered initial production, a key step toward full-volume manufacturing.

The turnaround effort began under former CEO Pat Gelsinger and has continued under current CEO Lip-Bu Tan, who has focused on aggressive cost-cutting while driving the foundry arm to secure external manufacturing deals. That strategy is now benefiting from favorable industry dynamics. TSMC, the world’s largest chip manufacturer, has been unable to provide enough capacity for all of its customers, forcing fabless chip companies — those without their own manufacturing capabilities — to seek alternative production partners. Intel has emerged as one of the few viable options.

The AI Tailwind Beneath It All

Underpinning the entire Intel story is the AI build-out and a structural shift in chip demand. While graphics processing units remain central to AI data centers, central processing units have become increasingly important as AI firms lean into agentic applications — digital assistants capable of performing tasks on a user’s behalf. As AI agents begin running more operations across networks, they increasingly rely on CPUs to complete requests, a segment where Intel holds genuine strength.

For investors tracking the broader semiconductor ecosystem, Intel’s resurgence carries a wider signal. The capacity constraints pushing major customers toward Intel are the same constraints reshaping the entire chip supply chain. Smaller semiconductor companies, specialty foundry service providers, and advanced packaging firms operating in adjacent parts of that supply chain are positioned within the same demand environment driving Intel’s recovery. When the largest chip customers cannot get enough capacity from the dominant manufacturer, the effects ripple across the entire sector — and the smaller companies serving that demand are worth watching closely.

Intel was left for dead a year ago. A 500% move later, the turnaround is no longer a thesis. It is happening.

Release – Codere Online Announces 2026 Annual General Meeting of Shareholders

Posted on by [email protected]
Codere Online logo

Research News and Market Data on CDRO

06/17/2026

Luxembourg, Grand Duchy of Luxembourg, June 17, 2026 (GLOBE NEWSWIRE) – Codere Online Luxembourg, S.A. (Nasdaq: CDRO / CDROW) (the “Company” or “Codere Online”), a leading online gaming operator in Spain and Latin America, today announced that its 2026 Annual General Meeting of Shareholders (“AGM”) will be held on June 30, 2026 at 1:00 PM CET at the registered office of the Company.

The convening notice of the AGM, including the agenda, proposed resolutions, and voting instructions, as well as a report from the Company’s board of directors for points 23 and 24 of the agenda are available on the Shareholders Meetings section of the Company’s website at codereonline.com and are being furnished to the U.S. Securities and Exchange Commission on Form 6-K.

Shareholders of record as of the close of business on June 11, 2026 are entitled to attend and vote at the meeting.

About Codere Online

Codere Online refers, collectively, to Codere Online Luxembourg, S.A. and its subsidiaries. Codere Online launched in 2014 as part of the renowned casino operator Codere Group. Codere Online offers online sports betting and online casino through its state-of-the art website and mobile applications. Codere currently operates in its core markets of Spain, Mexico, Colombia, Panama and Argentina. Codere Online’s online business is complemented by Codere Group’s physical presence throughout Latin America, forming the foundation of the leading omnichannel gaming and casino presence.

For more information, please contact:

Investors and Media
Guillermo Lancha
Director, Investor Relations and Communications
[email protected]
(+34) 628.928.152

Release – GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant Cancers

Posted on by [email protected]
GeoVax

Research News and Market Data on GOVX

Recent Publication and Growing Industry Focus on Immune-Priming Strategies Support Continued Evaluation of Gedeptin® as a Potential Complement to Checkpoint Inhibitor Therapy

ATLANTA, GA – June 17, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines for solid tumors and infectious diseases, today highlighted the broader oncology and strategic implications of recently published research supporting the potential of its Gedeptin® platform to enhance immune checkpoint inhibitor activity and address one of the most significant challenges in modern cancer treatment: improving responses in checkpoint-resistant tumors.

The update follows publication of the peer-reviewed article, “Broadening Activity of Checkpoint Blockade Agents by Intratumoral Nucleoside Cleavage,” in JCI Insight. The study reported findings supporting the potential for Gene-Directed Enzyme-Prodrug Therapy (GDEPT) to enhance checkpoint inhibitor responses, activate systemic anti-tumor immunity, and generate anti-tumor effects in both treated and distant untreated tumors in preclinical models of checkpoint-resistant triple-negative breast cancer.

While the publication focused on the underlying scientific findings, GeoVax views the results as further validation of broader trends shaping the future of cancer immunotherapy, including increasing industry emphasis on immune-priming approaches designed to improve checkpoint inhibitor responsiveness and overcome treatment resistance.

Addressing the Challenge of Checkpoint Resistance

Checkpoint inhibitors targeting pathways, such as PD-1 and PD-L1, have transformed treatment paradigms across multiple cancer types and now represent foundational therapies in modern oncology. Despite their success, many tumors remain poorly responsive to checkpoint blockade due to limited immune-cell infiltration, poor antigen presentation, and immunosuppressive tumor microenvironments.

These so-called “cold” tumors represent one of the most significant barriers to effective immunotherapy. Without sufficient immune recognition and engagement, even highly active therapies may struggle to generate durable clinical responses.

GeoVax recently explored this challenge in an Onco’Zine commentary authored by Chairman and Chief Executive Officer David Dodd entitled, “The Cold Tumor Barrier: Why Promising Oncology Therapies Fail In Vivo – and What It Will Take to Overcome It”. The article discussed the growing recognition that future advances in immuno-oncology may depend not only on developing new therapies, but also on improving the responsiveness of tumors to existing treatments through immune activation and tumor microenvironment modulation.

As a result, substantial research and development efforts across the oncology sector are increasingly focused on identifying therapies capable of converting immunologically cold tumors into more responsive tumors, potentially expanding the number of patients who may benefit from immunotherapy and improving outcomes with established checkpoint inhibitor regimens.

“One of the most significant challenges in oncology today is the cold tumor barrier,” said David Dodd, Chairman and Chief Executive Officer of GeoVax. “Checkpoint inhibitors can be highly effective when sufficient immune activity already exists within a tumor. However, many tumors remain largely invisible to the immune system. The next major opportunity may lie in therapies capable of activating immune recognition and making these tumors more responsive to existing immunotherapies.”

Positioning Gedeptin Within an Emerging Immunotherapy Paradigm

GeoVax sees potential for Gedeptin to play a differentiated role within this evolving treatment landscape. The recently published findings suggest that localized treatment may not only destroy targeted tumor cells, but also remodel the tumor microenvironment, promote immune activation, and enhance responsiveness to checkpoint inhibitors. These characteristics are increasingly viewed as important components of next-generation combination immunotherapy strategies.

The Company views Gedeptin’s combination of localized tumor destruction, strong bystander killing effects, tumor microenvironment remodeling, and immune activation as a potentially differentiated approach to addressing treatment resistance.

“Importantly, Gedeptin is not necessarily intended to directly compete with checkpoint inhibitors, but rather to complement them,” continued Mr. Dodd. “The medical proposition is to improve responses where checkpoint inhibitors alone have not achieved their full potential; also representing a significant commercial opportunity with multiple partnering avenues.”

Focus on Neoadjuvant Combination Strategies

GeoVax’s lead clinical development focus for Gedeptin is a planned neoadjuvant study in recurrent head and neck squamous cell carcinoma (HNSCC), evaluating intratumoral Gedeptin in combination with PD-1-based immunotherapy and standard of care, in patients with first recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) eligible for curative-intent surgery.

The Company considers recurrent head and neck cancer an attractive initial development setting because tumors are frequently accessible for direct injection, checkpoint inhibitors are already integrated into standard of care treatment paradigms, and substantial unmet need remains despite advances in immunotherapy.

GeoVax also views the neoadjuvant setting as particularly well suited for immune-priming approaches because the intact tumor can serve as a source of tumor antigens capable of stimulating broader anti-tumor immune responses prior to surgical resection.

“As checkpoint inhibitors continue moving earlier in the treatment paradigm, opportunities are emerging for therapies designed to improve immune responsiveness before surgery and potentially improve long-term outcomes,” said Mr. Dodd. “Gedeptin’s biologic profile appears well aligned with this evolving treatment strategy.”

Broader Platform Opportunities

Beyond head and neck cancer, GeoVax sees potential applicability for Gedeptin across multiple solid tumor settings where checkpoint inhibitors are established standard of care but response rates remain suboptimal.

“The oncology community is increasingly focused on improving response rates to existing immunotherapies and overcoming the cold tumor barrier,” added Mr. Dodd. “The emerging data support continued evaluation of Gedeptin as a differentiated immune-priming platform designed to complement existing immunotherapies and potentially broaden the impact of checkpoint blockade across multiple tumor settings.”

About Gedeptin®

Gedeptin® is GeoVax’s proprietary gene-directed enzyme prodrug therapy (GDEPT) platform under development for the treatment of solid tumors. The therapy utilizes a non-replicating adenoviral vector encoding purine nucleoside phosphorylase (PNP). Following administration of fludarabine, the PNP enzyme converts the prodrug into a potent localized cytotoxic compound within the tumor microenvironment.

GeoVax is advancing development plans evaluating Gedeptin in combination with checkpoint inhibitors, including pembrolizumab-based regimens, with the goal of improving anti-tumor immune responsiveness across multiple solid tumor indications.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

[email protected]

678-384-7220

Media Contact:

Jessica Starman

[email protected] 

Release – First Phosphate Announces Investment and Offtake Agreements under Critical Minerals Resilience and Production Alliance at G7 Summit

Posted on by [email protected]
First Phosphate Corp.

Research News and Market Data on FRSPF

June 17, 2026 10:59 AM EDT | Source: First Phosphate Corp.

Saguenay-Lac-Saint-Jean, Québec–(Newsfile Corp. – June 17, 2026) – First Phosphate Corp. (CSE: PHOS) (OTCQX: FRSPF) (OTCQX ADR: FPHOY) (FSE: KD0) (“First Phosphate” or the “Company“) is pleased to announce that it has formalized international investment and offtake agreements under the Critical Minerals Resilience and Production Alliance (the “Alliance”) at the 52nd G7 Summit in Évian, France.

Letters of interest:

Within the framework of the Alliance, First Phosphate is also pleased to announce that it has received letters of interest (“LOIs”) from export credit agencies, financial institutions and industrial partners:

  1. LOI for up to CDN $275M guarantee from the Export and Investment Fund of Denmark (“EIFO”) for the development of the First Phosphate Bégin-Lamarche mine. (signed March 30, 2026)
  2. LOIs from the Italian Export Credit Agency (“SACE”), from Italy’s National Promotional Institution, Cassa Depositi e Prestiti (“CDP”), and from the international growth partner for Italian companies (“SIMEST”), alongside the support of the Italian engineering group MAIRE (“MAIRE”), in relation to First Phosphate’s phosphoric acid (“PA”) plant at Port Saguenay to deploy Ballestra S.p.A (Italy) (“Ballestra”) technology. (LOIs signed between May 26, 2026 – June 4, 2026)

Offtake Agreements:

  1. Definitive offtake agreement with an international partner for a minimum of 200,000 tonnes per annum of phosphate concentrate from the Bégin-Lamarche mine. (signed January 5, 2026).
  2. Definitive offtake agreement with an international partner for a minimum of 60,000 tonnes per annum of phosphoric acid to be produced by the phosphoric acid plant at Port Saguenay. (signed December 16, 2024)

“Canada has what the world wants, and we are delivering. By working with trusted allies through the Critical Minerals Resilience and Production Alliance, investments are being made, projects are coming online faster, and we are strengthening supply chains in Canada and beyond,” said the Honourable Tim Hodgson, Canada’s Minister of Energy and Natural Resources. “By advancing projects like the Bégin-Lamarche mine, we’re securing the materials essential to the clean energy transition, creating good Canadian Jobs, and positioning Canada as a leader in an increasingly competitive global economy.”



To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8917/301865_a30ad39e14f0489d_001full.jpg

“These offtake and investment agreements announced under the Critical Minerals Resilience and Production Alliance at the 2026 G7 Summit demonstrate the strategic importance being assigned to establishing a secure, traceable and robust international supply chain for critical battery-grade phosphate material,” stated John Passalacqua, CEO of First Phosphate. “We are proud to lead the G7 in the development of this clean, rare igneous phosphate material from Saguenay-Lac-St-Jean, Quebec into a downstream lithium iron phosphate (“LFP”) battery supply chain for the G7 Alliance.”



To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8917/301865_a30ad39e14f0489d_002full.jpg

Qualified Person

The scientific and technical information relating to First Phosphate contained in this press release has been reviewed and approved by Steeve Lavoie, P.Geo., Chief Geologist of First Phosphate, who is Qualified Person within the meaning of National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”).

About First Phosphate Corp.

First Phosphate (CSE: PHOS) (OTCQX: FRSPF) (OTCQX ADR: FPHOY) (FSE: KD0) is a mineral exploration and development and clean technology company dedicated to building and reshoring a vertically integrated mine-to-market supply chain for the production of LFP batteries in North America. Target markets include energy storage, data centers, robotics, mobility, and national security. First Phosphate’s flagship Bégin-Lamarche property, located in Saguenay-Lac-Saint-Jean, Québec, Canada, represents a rare North American igneous phosphate resource producing high-purity phosphate characterized by very low levels of impurities.

About the Critical Minerals Resilience and Production Alliance

The Critical Minerals Resilience and Production Alliance was launched by Prime Minister Carney in June 2025 at the 51st G7 Leaders’ Summit in Kananaskis, Alberta. It brings trusted countries together to diversify critical minerals supply, promote responsible development, and reduce market concentration. The Alliance helps critical minerals projects move from planning to production faster by connecting governments, investors, and companies unlocking financing; securing investment; and supporting offtake agreements with long-term buyers, reducing risk so that mining and processing projects can get built and deliver secure, reliable supply.

About Export and Investment Fund of Denmark (EIFO)

EIFO is the Danish export credit agency backed by the Danish state, and as such, the EIFO guarantee can be considered AAA rated. The guarantee can be provided to one or more banks providing the funding and EIFO participation can be expected to be pro rata and pari passu with other senior lenders. EIFO has been involved in the financing of a significant number of transactions and projects around the world and has extensive experience within the field of export and project finance.

About Italian Export Credit Agency (SACE)

SACE is Italy’s Export Credit Agency, wholly owned by the Ministry of Economy and Finance. It specializes in supporting the growth of Italian companies through a wide range of instruments and solutions to foster exports and competitiveness, including risk management and protection, financial guarantees, factoring, advisory services, and business matching. With a network of export advisors across 23 offices in Italy and in high-potential markets for Made in Italy, SACE manages a portfolio of insured operations and guaranteed investments worth around €290 billion across 200 markets worldwide.

About Cassa Depositi e Prestiti (CDP)

Cassa Depositi e Prestiti is the National Promotional Institute which has been supporting the Italian economy since 1850. The main goal of CDP is to accelerate the industrial and infrastructural development of Italy to boost its economic and social growth. CDP focuses its activities on sustainable development at local level, supporting the innovation and growth of Italian enterprises, also in the international arena. It partners local authorities, in a financing and advisory capacity, to create infrastructures and improve services of public value. CDP also participates actively in international cooperation initiatives to realize projects in developing countries and emerging markets. Cassa Depositi e Prestiti is entirely financed by private capital, through the issuing of Postal Savings Bonds and Postal Savings Passbooks, and through issues on national and international financial markets.

About Società Italiana per le Imprese all’Estero (SIMEST)

SIMEST is the Cassa Depositi e Prestiti Group company that has been supporting Italian businesses since 1991 as they grow through internationalisation. SIMEST supports businesses throughout their international expansion process, from the initial evaluation to enter a new market, to expansion through direct investments. It operates through loans for international expansion, export credit assistance and equity investments in companies.

About MAIRE Group

MAIRE S.p.A. (EURONEXT MILAN: MAIRE IM) is a leading engineering group providing technology solutions and project execution in the downstream segment of energy services, as well as in the chemicals and fertilizers industries. The Group operates through two business units: Integrated E&C Solutions and Sustainable Technology Solutions, the latter active in sustainable fertilizers, low carbon energy vectors, and innovative materials and circular solutions. With operations in around 50 countries, MAIRE employs over 10,800 people. For further information: www.groupmaire.com

About Ballestra S.p.A

Ballestra S.p.A. is an Italian engineering company active in the licensing, design and engineering of processing plants, as well as in the supply of proprietary technologies and equipment for the chemical industry, including detergents, surfactants, phosphate- and potassium-based fertilizers, fluorine derivatives and gas-liquid reactions. Leveraging its know-how in sulfuric and phosphoric acid, it supports the processing of critical raw materials, with applications in lithium-ion batteries and in the metals and mining industries. Recently acquired by NEXTCHEM (subject to closing), part of MAIRE Group, it operates in over 120 countries and employs approximately 450 people.

For additional information

Armand MacKenzie
President
Tel : +1 (514) 618-5289

Investor Relations: https://firstphosphate.com/investors
General Inquiries: https://firstphosphate.com/contact
Website: www.FirstPhosphate.com

X: https://x.com/FirstPhosphate
LinkedIn : https://www.linkedin.com/company/first-phosphate

Forward-Looking Information and Cautionary Statement

This release includes certain statements that may be deemed “forward-looking information”. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. In particular, this press release contains forward-looking information relating to, among other things: the advancement of its exploration, development and downstream mine-to-market operations; statements about the Company’s business prospects, future trends, plans, and strategies; the entering into of definitive offtake and financing agreements, and any related transactions, and the structure, terms and conditions of the definitive agreements any related transactions; the design, build, operation and maintenance of the phosphate concentrate and a phosphoric acid manufacturing plant; and the receipt of regulatory approvals.

Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, development and exploration successes, and continued availability of capital and financing and general economic, market or business conditions. These statements are based on a number of assumptions including, among other things, assumptions regarding general business and economic conditions that engineering and construction timetables and capital costs for the Company’s, exploration, development and expansion projects are correctly estimated and not affected by unforeseen circumstances; the ability to obtain financing for its proposed operations on acceptable terms; no material deterioration in general business and economic conditions; no material delays in obtaining permits and other approvals; no significant disruptions affecting the activities of the Company or its ability to access required project equipment and services, and operating supplies in sufficient quantities and on a timely basis; inflation and prices for Company project inputs being approximately consistent with anticipated levels; the ability to complete the exploration and development programs consistent with the Company’s expectations; commodity price expectations including assumptions for P2O5; the Company’s relationship with local municipalities and First Nations remaining consistent with the Company’s expectations; the Company’s relationship with other third-party partners and suppliers remaining consistent with the Company’s expectations; and government relations and actions being consistent with Company expectations. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. The Company does not assume any obligation to update or revise its forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law. All forward-looking information contained in this release is qualified by these cautionary statements.

info

Source: First Phosphate Corp.

Release – Kratos Completes Cross-Country Autonomous Tractor-Trailer Deployment Supporting NASCAR Race Logistics

Posted on by [email protected]
Primary Logo

Research News and Market Data on KTOS

June 17, 2026

PDF VersionAutonomy Advances from Proven Motorsports Deployment to Long-Haul Logistics Operations

SAN DIEGOT, June 17, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a Technology Company in the Defense, National Security, and Global Markets, today announced the successful completion of a cross-country autonomous tractor-trailer platooning deployment transporting critical race equipment from Charlotte, North Carolina to Naval Base Coronado in support of the NASCAR Anduril 250.

Kratos completes cross-country unmanned truck platooning deployment in support of NASCAR.

Kratos completes cross-country unmanned truck platooning
deployment in support of NASCAR.

A photo accompanying this announcement is available at 
https://www.globenewswire.com/NewsRoom/AttachmentNg/d878f9bf-347c-45aa-b086-a4f2e3f51ce9

The deployment was conducted in collaboration with Champion Tire & Wheel, a leading motorsports logistics provider supporting NASCAR operations, and built on the successful 2025 auto-platooning deployment supporting the Brickyard 400 at Indianapolis Motor Speedway. The Anduril 250 cross-country deployment expanded the capability into a multi-state, long-haul logistics operation, further demonstrating Kratos’ dual-use innovation strategy of adapting proven defense autonomy for commercial deployment.

“Last year proved the concept. This year demonstrated scalable execution,” said Maynard Factor, Vice President of Business Development at Kratos. “Our autonomous follower tractor-trailer successfully completed a cross-country logistics haul, demonstrating how platooning technology can safely improve efficiency, expand freight capacity, and help address ongoing driver shortages.”

Kratos’ autonomous truck platooning system pairs a human-driven lead tractor-trailer with an autonomous follower tractor-trailer supervised by an onboard safety rider. Using synchronized steering, braking, and speed control, the follower vehicle traveled as part of a multi-state freight deployment while maintaining safety and operational oversight. A layered autonomy approach combining GPS, onboard sensors, and advanced vehicle controls enabled operation across dynamic roadway and environmental conditions.

Kratos’ NASCAR deployment demonstrated the maturity of autonomous freight movements from controlled pilot programs into revenue-generating commercial logistics operations. By enabling a single driver to support multiple vehicles, leader-follower autonomous platooning offers a practical path toward increasing freight capacity, improving operational efficiency, and expanding the use of autonomy across both commercial transportation and defense logistics applications.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 28, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
[email protected]

Kratos Investor Information:
877-934-4687
[email protected]

Release – Graham Corporation Appoints Jonathan W. Painter as Chairman of the Board

Posted on by [email protected]
Graham Corporation

Research News and Market Data on GHM

June 17, 2026 7:30am EDT Download as PDF

Daniel J. Thoren to Retire and Step Down as Executive Chairman, Continue as Strategic Advisor Through June 2027

BATAVIA, N.Y.–(BUSINESS WIRE)– Graham Corporation (NYSE: GHM), a global leader in the design and manufacture of mission critical fluid, power, heat transfer, vacuum, and advanced mixing technologies for the defense, space, energy, and process industries, today announced that Jonathan W. Painter has been appointed Chairman of the Board of Directors, effective June 15, 2026. The appointment follows the decision by Daniel J. Thoren to retire and step down from his role as Executive Chairman and as a Director as part of the executive transition plan announced in February last year. Mr. Thoren will continue to serve as a Strategic Advisor to the Company through June 2027 with a focus on business development initiatives.

Mr. Painter previously served as Chairman of the Board until June 2025, when he transitioned to Lead Independent Director as part of the Company’s CEO succession plan. As part of Mr. Thoren’s planned transition, Mr. Painter will reassume the Chairman role, providing governance continuity as the leadership transition has been completed.

Mr. Thoren’s retirement from the Board of Directors marks the next phase of the CEO succession plan announced in February 2025. Following his transition, the Board will return to seven directors, consistent with its prior structure, having been temporarily expanded to eight members to support the leadership transition.

Mr. Thoren transitioned from President and CEO to Executive Chairman in June 2025, focusing on business development activities and working closely with CEO, Matthew J. Malone and the leadership team on strategic initiatives.

Jonathan W. Painter, Chairman of the Board of Directors, said “I am honored to reassume the role of Chairman as we complete the next phase of our planned leadership transition. On behalf of the Board, I want to express our deep gratitude to Dan for his exceptional contributions to Graham Corporation over the last five years. His leadership as CEO and Executive Chairman has been instrumental in positioning the company for continued success. Under Matt’s leadership over the past year, Graham has performed exceptionally well, and I have complete confidence in his vision and ability to drive the company forward. The Board remains committed to supporting Matt and the entire leadership team as we pursue our strategic objectives and create value for our shareholders.”

Daniel J. Thoren, Executive Chairman, said “It has been a privilege to serve Graham Corporation in various leadership roles, and I am incredibly proud of what we have accomplished together. Matt has done an exceptional job since taking over as CEO a year ago, and I have full confidence in his leadership and the strength of the team he has built. Now feels like the right time for me to step back, knowing the Company is in excellent hands, and well-positioned for future growth. I look forward to continuing to support Graham as a Strategic Advisor and completing the initiatives I have been working on.”

Mr. Malone assumed the role of President and CEO in June 2025, following a carefully planned succession process. Under his leadership, the Company has delivered strong operational and financial performance.

About Graham Corporation

Graham is a global leader in the design and manufacture of mission critical fluid, power, heat transfer, vacuum, and advanced mixing technologies for the Defense, Space, Energy, and Process industries. Graham Corporation and its family of global brands are built upon world-renowned engineering expertise, proprietary technologies, as well as its responsive and flexible service and the unsurpassed quality customers have come to expect from the Company’s products and systems. Graham Corporation routinely posts news and other important information on its website, grahamcorp.com, where additional information on Graham Corporation and its businesses can be found.

Safe Harbor Regarding Forward Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects,” “future,” “believe,” “will,” “plan” and other similar words. All statements addressing operating performance, events, or developments that Graham Corporation expects or anticipates will occur in the future, including but not limited to, expected future management personnel changes and the timing of such changes, expected expansion and growth opportunities, and its growth strategy, are forward-looking statements. Because they are forward-looking, they should be evaluated in light of important risk factors and uncertainties. These risk factors and uncertainties are more fully described in Graham Corporation’s most recent Annual Report filed with the Securities and Exchange Commission (the “SEC”), included under the heading entitled “Risk Factors”, and in other reports filed with the SEC.

Should one or more of these risks or uncertainties materialize or should any of Graham Corporation’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Graham Corporation’s forward-looking statements. Except as required by law, Graham Corporation disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this news release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260617290539/en/

Christopher J. Thome
Vice President – Finance and CFO
Phone: (585) 343-2216

Tom Cook
Investor Relations
Phone: (203) 682-8250
[email protected]

Source: Graham Corporation

Released June 17, 2026

Vince Holding Corp. (VNCE) – Momentum Accelerates; Guidance Raised

Posted on by [email protected]


Wednesday, June 17, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Strong Q1 results and accelerating momentum. First-quarter revenue growth of $64.0 million, exceeding the high end of management’s guidance range, while adjusted EBITDA improved to a loss of $1.1 million from a loss of $3.0 million in the prior-year period. The quarter marked another step forward in the company’s transition from a turnaround story to a growth and earnings expansion story, with strength across both Direct-to-Consumer (DTC) and wholesale channels.

Growth driven by DTC and pricing. DTC sales rose 15.6%, wholesale sales increased 5.9%, and gross margin expanded despite tariff pressures, driven by higher pricing, lower discounting, and strong customer acquisition.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Bed Bath & Beyond Is Acquiring a Real Estate Company. The Strategy Behind It Is More Interesting Than It Sounds

Posted on by [email protected]

In one of the more unexpected M&A announcements of the year, Bed Bath & Beyond (NYSE: BBBY) has entered into a definitive agreement to acquire Fathom Holdings (Nasdaq: FTHM), a national technology-driven real estate services platform, in an all-stock transaction. The deal implies an equity value of approximately $53.38 million for Fathom and reflects an exchange ratio of 0.2236 shares of Bed Bath & Beyond common stock for each Fathom share, subject to adjustments at closing. The transaction is expected to close in the second half of 2026, pending Fathom shareholder approval and customary regulatory clearances.

At first glance, a home goods retailer acquiring a real estate brokerage appears to make little sense. The logic becomes considerably clearer once you understand what Bed Bath & Beyond is actually trying to build.

The “Everything Home” Strategy

Bed Bath & Beyond — which operates today as a digital-first brand following its well-documented restructuring and relaunch under the Beyond corporate umbrella — is pursuing a strategy it calls “Everything Home.” The concept is built around three interconnected pillars: Homeownership and Transactions, Omnichannel Commerce, and Home Services. The goal is to own the entire lifecycle of a home, from the moment a consumer buys it, to financing it, to furnishing it, to maintaining it over time.

The Fathom acquisition slots directly into the Homeownership and Transactions pillar. Fathom is not simply a brokerage. It is an integrated platform combining residential real estate brokerage, mortgage origination through Encompass Lending, title services through Verus Title, insurance, and a proprietary cloud-based software platform called intelliAgent. By acquiring Fathom, Bed Bath & Beyond gains an established foothold across the financial and transactional side of homeownership that it could not easily build organically.

The Cross-Selling Thesis

The strategic appeal is the connection point between buying a home and furnishing one. Bed Bath & Beyond’s core business is selling products for the home. Fathom’s business is helping people buy and finance those homes. The combination creates a theoretical funnel: reach a consumer at the moment they purchase a home through Fathom’s brokerage and lending operations, then convert that same consumer into a furnishing and home goods customer through Bed Bath & Beyond’s omnichannel commerce platform.

Fathom, for its part, gains access to Bed Bath & Beyond’s nationally recognized brand, millions of existing customers, and significantly greater capital resources to invest in its technology platform and agent network. For a company with an equity value of roughly $53 million, access to a large consumer brand’s customer base and balance sheet represents a meaningful expansion of reach that would be difficult to achieve independently in the current real estate environment.

Alongside the announcement, Fathom named board member Adam Rothstein as Interim Chief Executive Officer and appointed Daniel Weinmann as Chief Financial Officer, both effective immediately.

The Small Cap Read

For investors tracking the small and microcap space, this deal is worth examining for what it represents rather than just its size. A $53 million all-stock acquisition is small by absolute standards, but it reflects a broader theme: companies are increasingly pursuing platform strategies that combine previously unrelated business lines around a single customer relationship. Real estate technology, in particular, has faced significant headwinds from elevated mortgage rates and suppressed transaction volumes, making smaller players like Fathom attractive targets for acquirers with complementary customer bases and the capital to support a longer-term vision.

Whether the homeownership-to-furnishing funnel ultimately delivers the cross-selling synergies both companies envision will take time to prove. But the strategic logic — owning the customer across the entire arc of homeownership rather than at a single transaction point — reflects exactly the kind of platform thinking that is driving M&A activity across the consumer economy in 2026.